BioVie Inc. (the “Company” or “we” or “our”) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. Neurodegenerative Disease Programs The Company acquired the biopharmaceutical assets of NeurMedix, Inc.
Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.
Share structure
Common
7.5M
Pre-funded warrants
0.4M
Options
2.8M
RSUs
0.0M
Warrants
7.9M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
—
FDSO
18.6M
Cap table as of 2026-06-30.
Price history
Loading BIVI daily closes…
Loading price history…
Recently reported
bezisterim Phase 2Mixed · 2026-10-20
SUNRISE-PD · early Parkinson's disease
Primary: Effect of bezisterim on hematologic inflammatory biomarker indices (MLR, SIRI, NLR, SII, PLR, AISI) and a composite of those markers (primary pharmacodynamic endpoint) — not disclosed
· Prespecified high-inflammation subgroup (above-median platelet counts above 230 x 10^9/L): MDS-UPDRS Part I (non-motor) -1.62 vs +1.86 for placebo (Cohen's d = -1.33; p=0.0124)
· Same subgroup: MDS-UPDRS Part III (motor) -1.32 vs +1.26 for placebo (Cohen's d = -0.92; p=0.0265)
· Same subgroup: MDS-UPDRS Total Scores -1.23 vs +1.21 for placebo (Cohen's d = -1.45; p=0.0006)
· Clinically meaningful improvement on the Composite Benefit Score: 25% on bezisterim vs 4% on placebo (6.25-fold more likely)
· Clinically meaningful worsening: 14% on bezisterim vs 46% on placebo (relative risk 0.30); randomized, double-blind, placebo-controlled, n=57, 20 mg twice daily for 12 weeks (NCT06757010)
Safety: Well tolerated: treatment-emergent adverse events 39.3% on bezisterim vs 51.7% on placebo; no severe or serious adverse events in either group; one potentially treatment-related adverse event in each arm
Primary: Effect on hematologic inflammatory biomarker indices (MLR, SIRI, NLR, SII, PLR, AISI) in early Parkinson's disease (SUNRISE-PD, NCT06757010); clinical endpoints secondary/exploratory — In the prespecified subgroup with higher baseline systemic inflammation (above-median platelet counts above 230 x 10^9/L), bezisterim improved MDS-UPDRS Total Scores -1.23 vs +1.21 for placebo (Cohen's d = -1.45; p=0.0006)
· MDS-UPDRS Part I (non-motor) -1.62 vs +1.86 placebo (Cohen's d = -1.33; p=0.0124) in the high-inflammation subgroup
· MDS-UPDRS Part III (motor) -1.32 vs +1.26 placebo (Cohen's d = -0.92; p=0.0265) in the high-inflammation subgroup
· Composite Benefit Score favored bezisterim in the overall mITT population (Cohen's d = -1.61; p=0.0004)
· Clinically meaningful improvement on CBS: 25% bezisterim vs 4% placebo (6.25-fold more likely)
Status note Phase 3 trial in mild to moderate probable AD (NCT04669028) topline announced Nov 29, 2023; securities class action re NM101 Phase 3/AD trial pending (class certification briefing due Jun 15, 2026). Phase 2b SUNRISE-PD topline announced; Phase 2 ADDRESS-LC in long COVID ongoing.
BIV201
Stage not disclosed · Active
Indications
Cirrhosis with ascites / refractory ascites(Stage not disclosed)
Status note Liver program. Finalizing Phase 3 protocol design for cirrhosis/ascites following FDA discussions in 2023 and 2025; no Phase 3 trial initiated per this filing.
Per-asset detail extracted from the 10-Q filed 2026-05-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.